ANDA 75189, held by Impax Labs Inc. Nabumetone.
As of Nov 15, 2026, ANDA 75189 (Nabumetone), held by Impax Labs Inc, was first approved by FDA on May 26, 2000, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 2000 | Original application | Approved |
| Nabumetone500MG · tablet;oral | Nabumetone | Discontinued |
| Nabumetone750MG · tablet;oral | Nabumetone | Discontinued |
| Nov 21, 2024 | Supplement 32Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 31Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 26Labeling · Standard review | Approved | None posted |
| Nov 10, 2009 | Supplement 18Labeling | Approved | None posted |
| May 19, 2006 | Supplement 16Labeling | Approved | None posted |
| Mar 17, 2006 | Supplement 14Labeling | Approved | None posted |
| Mar 2, 2006 | Supplement 12Labeling | Approved | None posted |
| Jun 21, 2002 | Supplement 3Manufacturing | Approved | None posted |
| May 21, 2002 | Supplement 4Labeling | Approved | None posted |
| Sep 24, 2001 | Supplement 1Manufacturing | Approved | |
| Sep 24, 2001 | Supplement 2Labeling | Approved | |
| May 26, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters